Table 4.

Adjuvant therapy, recurrence and outcome of long-term survival cases of adult undifferentiated embronal sarcoma

Reference	Year	Age	Resection margin	Adjuvant treatment	Recurrence	Treatment for recurrence	Follow-up months)	Outcome
Grazi [9]	1996	25	Positive	None	Liver	Re-resection, two times	67.6	DOD
Alomogy [17]	2005	21	Negative	I + ADM, Re-resectionI + ADM	None		77	NED
Lenze [16]	2008	34	Negative	None	Liver	CBDCA + VP-16  + ADM + I	72	NED
Present	2011	27	Negative	DDP + VCR + ADM + ACTRT + PBSCT (VP-16, MCNU, CBDNU, CBDCA, CTX)	None		60	NED

ACT, actinomycin D; ADM, doxorubicin; CBDCA, carboplatin; CTX, cyclophosphamide; DDP, cisplatin; DOD, dead of disease; I, ifosfamide; MCNU, ranimustine, NED, no evidence of disease; PBSCT, pheripheral blood stem cell transplantation; RT, radiotherapy; VCR, vincritine; VP-16, Etoposide.